In:
Cancer, Wiley, Vol. 120, No. 24 ( 2014-12-15), p. 3902-3913
Abstract:
A vertically integrated, proteomics‐based biomarker discovery approach has been used successfully to develop and validate a 4‐protein serum biomarker panel (biglycan, myeloperoxidase, annexin‐A6, and protein S100‐A9 [B‐AMP]) for esophageal adenocarcinoma. Because of its ease of serum sample collection and analysis at relatively low cost, B‐AMP holds significant promise for early, noninvasive detection and monitoring of esophageal adenocarcinoma.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v120.24
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1